Search details
1.
HPV-associated head and neck cancer is characterized by distinct profiles of CD8+ T cells and myeloid-derived suppressor cells.
Cancer Immunol Immunother
; 72(12): 4367-4383, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-38019346
2.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Article
in English
| MEDLINE | ID: mdl-32673417
3.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 373(19): 1803-13, 2015 Nov 05.
Article
in English
| MEDLINE | ID: mdl-26406148
4.
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Acta Oncol
; 54(7): 993-1000, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25924969
5.
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.
BMC Cancer
; 14: 624, 2014 Aug 28.
Article
in English
| MEDLINE | ID: mdl-25164437
6.
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.
Future Oncol
; 10(1): 21-40, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24328407
7.
Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.
Future Oncol
; 10(5): 823-33, 2014 Apr.
Article
in English
| MEDLINE | ID: mdl-24799063
8.
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Gut
; 62(5): 751-9, 2013 May.
Article
in English
| MEDLINE | ID: mdl-22773551
9.
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Invest New Drugs
; 30(5): 1962-71, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-21989836
10.
Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab.
Front Oncol
; 11: 635096, 2021.
Article
in English
| MEDLINE | ID: mdl-34055606
11.
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Eur Urol
; 72(6): 962-971, 2017 12.
Article
in English
| MEDLINE | ID: mdl-28262413
12.
Very late and isolated leptomeningeal relapse of a pulmonary adenocarcinoma presenting as dementia.
Onkologie
; 34(6): 316-20, 2011.
Article
in English
| MEDLINE | ID: mdl-21625185
13.
Circulating Tumor Cell Composition in Renal Cell Carcinoma.
PLoS One
; 11(4): e0153018, 2016.
Article
in English
| MEDLINE | ID: mdl-27101285
14.
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
Cancer Chemother Pharmacol
; 73(6): 1227-39, 2014 Jun.
Article
in English
| MEDLINE | ID: mdl-24714973
15.
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.
PLoS One
; 9(1): e85350, 2014.
Article
in English
| MEDLINE | ID: mdl-24465542
16.
Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.
Clin Lung Cancer
; 15(5): 320-30.e1-3, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-24993594
17.
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
J Thorac Oncol
; 8(1): 19-30, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23242435
18.
Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].
Eur Urol
; 73(4): e116-e118, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29306512
19.
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center.
Eur J Cancer
; 49(15): 3076-82, 2013 Oct.
Article
in English
| MEDLINE | ID: mdl-23876834
20.
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
J Thorac Oncol
; 7(9): 1440-8, 2012 Sep.
Article
in English
| MEDLINE | ID: mdl-22895141